CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 3.61: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
6.54BCNY976.81M · vs all stocks (USD)
Revenue (TTM)
378.04MCNY56.43M · vs all stocks (USD)
Profit Margin
-5.76%Beta
0.8870xvs all stocks
52-Week Change
14.93%vs all stocks
Market Capitalization
6.54BCNY976.81M · vs all stocks (USD)
Enterprise Value
5.67BCNY846.48M · vs all stocks (USD)
Forward P/E
-23.11xPrice to Sales (TTM)
17.17xPrice to Book (MRQ)
6.23xEnterprise to Revenue
15.00xProfit Margin
-5.76%Operating Margin
-579.17%Return on Assets (TTM)
-1.20%Return on Equity (TTM)
-2.10%Revenue (TTM)
378.04MCNY56.43M · vs all stocks (USD)
Revenue per Share (TTM)
1.02CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-46.70%Gross Profit (TTM)
281.47MCNY42.02M · vs all stocks (USD)
EBITDA (TTM)
-15.16MCNY-2.26M · vs all stocks (USD)
Net Income (TTM)
-21.77MCNY-3.25M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-42.94%Operating Cash Flow (TTM)
52.53MCNY7.84M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
82.38MCNY12.30M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
123.39MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
82.40MCNYFY2025 · Dec 31, 2025Gross Profit
40.99MCNYFY2025 · Dec 31, 2025Operating Income
-241.02MCNY-35.98M · vs all stocks (USD)
Pre-tax Income
-268.05MCNYFY2025 · Dec 31, 2025Net Income
-268.05MCNYFY2025 · Dec 31, 2025EBIT
-258.94MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-190.19MCNYFY2025 · Dec 31, 2025Research & Development
141.54MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
90.84MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.28MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.12MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.7200CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.7200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
372.30MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
372.30MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-268.05MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-305.82MCNYFY2025 · Dec 31, 2025Free Cash Flow
-335.65MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
170.34MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-268.05MCNYFY2025 · Dec 31, 2025Other Non-cash Items
9.22MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.87MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-19.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-29.83MCNYFY2025 · Dec 31, 2025Net Acquisitions
27.47MCNYFY2025 · Dec 31, 2025Sale of Investments
12.22MCNYFY2025 · Dec 31, 2025Other Investing Activity
162.82MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
172.68MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
361.85MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-362.62MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-8.19MCNYFY2025 · Dec 31, 2025Other Financing Charges
-15.46MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-24.42MCNYFY2025 · Dec 31, 2025Shares Outstanding
374.58MSharesUpdated Sep 22, 2026Float Shares
219.38MSharesUpdated Sep 22, 2026% Held by Insiders
41.22%vs all stocks
% Held by Institutions
10.67%vs all stocks
Total Cash (MRQ)
906.67MCNY135.34M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.42CNYUpdated Sep 22, 2026Total Debt (MRQ)
419.42MCNY62.61M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4057xCurrent Ratio (MRQ)
4.96xBook Value per Share (MRQ)
2.78CNYUpdated Sep 22, 2026Total Assets
1.58BCNY235.59M · vs all stocks (USD)
Total Current Assets
1.00BCNYFY2025 · Dec 31, 2025Total Liabilities
701.44MCNYFY2025 · Dec 31, 2025Total Non-current Assets
573.49MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
291.10MCNYFY2025 · Dec 31, 2025Total Current Liabilities
410.34MCNYFY2025 · Dec 31, 2025Cash
170.13MCNYFY2025 · Dec 31, 2025Cash Equivalents
212.12KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
170.34MCNYFY2025 · Dec 31, 2025Other Short-term Investments
542.79MCNYFY2025 · Dec 31, 2025Accounts Receivable
58.49MCNYFY2025 · Dec 31, 2025Inventory
66.62MCNYFY2025 · Dec 31, 2025Accounts Payable
47.06MCNYFY2025 · Dec 31, 2025Short-term Debt
326.05MCNYFY2025 · Dec 31, 2025Other Current Liabilities
49.01KCNYFY2025 · Dec 31, 2025Long-term Debt
82.86MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.59MCNYFY2025 · Dec 31, 2025Common Stock (Book)
374.58MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.22BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
876.87MCNY130.89M · vs all stocks (USD)
52-Week Low
13.06CNYUpdated Sep 22, 202652-Week High
29.98CNYUpdated Sep 22, 202652-Week Change
14.93%vs all stocks
Beta
0.8870xvs all stocks
50-Day MA
19.43CNYUpdated Sep 22, 2026200-Day MA
20.92CNYUpdated Sep 22, 2026Avg 10-Day Volume
12.42MSharesUpdated Sep 22, 2026Avg 30-Day Volume
16.15MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
-0.0600CNYUpdated Sep 22, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 17.17Revenue Growth YoY: -0.47
Financial Health
Altman Z-Score 3.61: safe zoneNotable
Altman Z-Score: 3.61
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Corvus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Procept BioRobotics Corporation
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Highfine Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Ausun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Huakang Century Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Edan Instruments Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Er-Kang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Northeast Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Guangdong Yangshan United Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hainan Haiyao Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Invivyd Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated